The Implications of the New Genomic Techniques Vote
Updated: Oct 3
Why This Vote on Crop Gene Editing Happened
Environmental Sustainability
NGT-1 crops are marketed as requiring less water, fewer pesticides, and less fertilizer. These are exactly the inputs Europe aims to reduce under its climate targets. With faster drought and disease resistance, these crops promise fewer failures as growing seasons become less predictable. The European Commission has been building this case since 2021, linking NGTs to the European Green Deal.
Social Sustainability
EU tillage and grain farmers have faced rising input costs, shrinking direct payments, and a dwindling list of approved plant protection products. The argument is that faster breeding can deliver resilient varieties to farmers sooner. This prevents them from relying on outdated tools from the 1990s during challenging seasons.
Economic Sustainability
Countries like the US, China, and those in South America have had more permissive gene-editing rules for years. The EU's approval process has lagged behind, creating a competitiveness cost. Eight years of legislative back-and-forth on this issue has frustrated many agricultural groups that pushed for this vote.
The Wrong Argument Everyone Is Having
The debate centers around safety, but that's the wrong question. The right one is: who decided that 20 genetic modifications is the pass mark?
The Scientific Debate Brussels Used to Justify the Vote
Detlef Weigel from Max Planck states that if a CRISPR-edited plant has no foreign DNA and only changes that could occur naturally, there’s no scientific reason to regulate it like a transgenic GMO.
Conversely, Michael Antoniou from King's College London argues that the CRISPR editing process can cause large-scale, unintended changes to the plant's DNA, sometimes affecting hundreds or thousands of sites. A mutation count of 20 does not capture this complexity.
Two scientists, two credible positions. Yet, the EU has set a pass mark of 20 modifications, creating a false sense of clarity.
The Question Nobody Is Naming
The environmental, social, and economic arguments led Brussels to drop traceability and labeling. None of these arguments required Brussels to address preventability.
NGT crops can still be patented. Critics argue this favors large corporations like Bayer, Syngenta, and Corteva over small and medium enterprises (SMEs) and farmer cooperatives that cannot absorb these costs.
Here’s the crucial question: Do faster climate adaptation, food security, and competitiveness truly require a patent regime? If urgency was genuine and the patent issue separate, why were both passed in the same vote?
It’s ironic how this aligns perfectly with the interests of a few large companies while leaving smaller cooperatives at a disadvantage.
The Pattern We See on Boards
This situation reflects a governance failure disguised as a scientific debate. We often see this pattern.
A board approves a strategy based on a seemingly rigorous number—20 modifications, 73% circularity, net zero by 2040—without questioning the underlying assumptions.
If you’ve written a sustainability strategy for your board this year, identify your version of 20 modifications. Every strategy has one. It’s the threshold everyone accepted because it had a number, not because anyone examined what that number truly represented.
How This Gets Done Right
Grade the Outcome, Not the Pass Mark
We should require genomic profiling pre-market, as Antoniou suggests, and make the results public. This approach combines Weigel's precision argument with Antoniou's safety argument, rather than relying on a single number that oversimplifies the issue.
Separate the Urgency Case from the Ownership Case
Fast-track approval for traits that genuinely contribute to environmental sustainability, food security, or competitiveness—like drought tolerance and pest resistance. However, do not fast-track patent rights in the same vote. If the goal is truly about industrial policy, it deserves a separate, thorough debate.
Price the Asymmetry
A small seed cooperative and Bayer do not face the same patent costs, even when both are addressing the same climate problem. If your regulations don’t account for this disparity, you haven’t accelerated climate adaptation; you’ve merely consolidated the market and handed diplomas to the same few.
Where This Leaves Boards
This is what we do for boards before the vote, not after the headlines. We identify the hidden pass marks in strategies and question their origins. What were they built to avoid measuring? Then we assess the costs involved.
If your sustainability or innovation strategy has a number like this embedded within it, you already know the one we’re discussing. Start there.
Totally agree with the author, this topic is super relevant right now. Some time ago I came across https://silukr.org and now I often use it as a reference for finding useful information. For related questions, I also occasionally check https://whatiscfdtrading.org/ which is another solid source. Has anyone else used them? What do you think of their content? Personally, it saves me a ton of time.